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After advances in clinical care and newer efforts in therapeutic 
approaches, life span has lengthened in Duchenne muscular 
dystrophy (DMD). Starting from eary 1980s, each decade lead to a 
five year gain. DMD is not simply a monogenic X-linked disorder, 
it is a multisystemic condition. Pulmonary, cardiac, endocrine, 
gastrointestinal, and bone health aspects need careful monitoring 
along with pyschology, physiotherapy, social and family as a whole. 
Molecular treatments are becoming facts, which some are already at 
hand. Some others are expected to be available within the next two 
years.
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Introduction
Duchenne muscular dystrophy (DMD) is an x–linked recessive genetic 
disorder that affects 1 in 3600-6000 male live births(9). Girls may be 
solely carriers or sometimes present with symptoms. DMD is caused by 
mutations in the dystrophin gene which results in a severe reduction or 
absence of stability. Lack of functional dystrophin results in degeneration 
of muscle fibres (1, 2). Becker muscular dystrophy (BMD) is also caused 
by dystrophin gene mutations. Typically it presents later and progresses 
more slowly. If a boy with dystrophin deficiency is still able to walk 
after the 16th birthday, he is considered as a BMD. 
Clinical features
The onset is usually after the child has walked, which is later than 18 
months in most cases as there is a delay in milestones. Early signs 
include difficulty with jumping, running, climbing steps and rising from 
the floor. Typically boys may display toe walking or a waddling gait. On 
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examination the child may have calf hypertrophy, 
hypotonia, or may demonstrate Gowers’ sign (the 
boys touches knees while raising from a squatting 
position and this duration is longer than 2-3 
seconds) (3). DMD is also associated with non-
motor manifestations. DMD children have a high 
prevalence of cognitive delay and learning and 
behavioural problems (4). Rarely austistic features 
is part of the spectrum. Speech delay and failure to 
thrive may be present in at least half of boys with 
DMD. DMD is always associated with high levels 
of creatine kinase (CK) Increased levels of lactate 
dehydrogenase (LDH), alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST). DMD 
should therefore be considered with unexplained 
rises in liver function dysfunction, even going as 
far as performing liver biopsies. In about half of the 
cases there is a family history denoting X-linked 
recessive inheritance, and the remaining half are 
de-novo mutations (3).
Diagnosis
Diagnosis should be made quite early, beacuse 
delays may lead to several medical and social 
complications. CK is is simple and inexpensive test 
which is very sensitive once the symptoms suffice 
the suspicion of DMD (5). The diagnosis of DMD 
is confirmed by genetic testing (6). About 70% 
of DMD is caused single or multi exon deletion 
or duplication studied by multiplex ligation-
dependent probe amplification (MLPA). If MLPA 
result do not show a visual abnormality, the second 
step is to sequence the gene in full (6). Female 
relatives of DMD patients hould be offered genetic 
testing for carrier status. A small number of female 
carriers might present with muscle symptoms, 
such as pain, cramps or weakness, and learning 
or behavioural problems (7). Female carriers are 
also at risk of heart problems (8). Cardiovascular 
monitoring is recommended for all female carriers 
every 3-5 years (6). Mothers of DMD patients, 
along with all female carriers of reproductive 
age, should be offered family planning early with 
discussion about possible pre-implantation or 
prenatal genetic testing. In most instances females 
only carry the abnormal gene with no symptoms 
due to X-inativation patterns. About 10% of female 
carriers are prone to develop muscle and cardiac 
symptoms as they age. Cardiac weakness is usually 
around age 40 or so. Serum CK is not the ideal test 
beacuse it may be normal. The gold standard test 
for carrier detection is the MLPA just like in boys. 
Other forms
Dilated cardiomyopathy: These patients usually 
have minimal or mild muscle weakness, however 
they develop overt cardiomyopathy by 20-30 years 
of age. The condition is due to lack of production 
of dytrophin exclusively in cardiac muscle (9-10). 
X-linked myoglubulinuria: This is also a rather 
mild condition in which patients do not mainfest 
muscle symptoms but there is myoglobulinuria 
mainly after exercise. The abnormality is the DMD 
gene is mostly in the mid-domain regions such as 
10-22 (11).
Treatment
Optimal care of DMD is best achieved by a 
multidisciplinary team. Speech and language 
therapists also have an important role in the overall 
clinical care of children with DMD. (3, 12). Cardiac 
monitoring is essential from diagnosis in view 
of the risk of dilated cardiomyopathy. Additional 
specialists, such as respiratory physicians should 
also be part of the care providing group.
Ambulation has been shown to be prolonged with 
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early initiation of glucocorticoid therapy (13), 
a mainstay of DMD treatment. Glucocorticoids 
(0.75 mg/kg/day of prednisolone or 0.9mg/kg/day 
of deflazacort on daily or intermittent regimes) 
improve muscle function over time, delay the 
development of respiratory complications, and 
postpone or avoid scoliosis, even cardiomyopathy 
3, 6). However, from a pediatrics perspective these 
recommended dosages are quite high (personal 
opinion) and can not be maintained on the long 
run. Glucocorticoid treatment is associated with 
side effects, including weight gain, cushingoid 
appearance, behavioural changes, delayed puberty, 
reduced growth, increased risk of fractures 
(including vertebral fractures), cataracts and hair 
growth (13, 14). A lower steroid dose may be 
required for patients who suffer from unacceptable 
side effects or do not tolerate the recommended 
dose. The child will stop to walk eventually and 
this is not preventable. It is outmost important 
to maintain muscle function and minimize 
contractures and deformity once walking is ceased. 
A team of physiotherapists, orthopaedic surgeons 
and occupational therapists are integral part of the 
health providing group. 
Primary care in DMD
Primary care is an age dependent approach. Younger 
children are follwed at routine intervals almost 
like healthy counterparts, except they deserve 
yearly cardiac examinations. As the boy grows 
older such as age beyond 11-12 closer monitoring 
should become in action. They should be provided 
appropriate vaccination such as pneumococcal 
vaccine and yearly influenza vaccines. While 
on steroids live vaccines should be avoided if 
possible. A proper nurtition and weight balance is 
of significant importance. Cardiovascular health 
and fitness should be encouraged. There is always 
the risk of adrenal insufficiency if steroids are 
stopped suddenly and this may create a case of 
emergency. DMD boys and their families may need 
psychological support over the follow-up preriods 
and this is natural (3, 6, 15).
During follow-up
Cardiac: Despite the protective effect of oral 
steroids, DMD is associated with a primary dilated 
cardiomyopathy, however this usually faced 
during later stage of the disease. This can lead to 
heart failure or arrhythmias. Children may not be 
symptomatic until very late in disease progression 
due to immobility. Patients may be investigated 
by ultrasound echocardiograms, cardiac MRI and 
24 hour holter monitoring. Cardiologists may 
start cardioprotective medications including ACE-
inhibitors and beta-blockers (16). The new trend 
is to initiate these medications early, even before 
symptoms start in a preventive manner.
Respiratory: DMD patients have an increased 
risk of respiratory complications. Vaccinations 
are a pre-requisite. Serial monitoring of lung 
function and sleep studies can detect deterioration 
in respiratory function, more likely to occur in the 
non-ambulant phase. Survival can be prolonged 
by lung volume recruitment, assisted coughing, 
nocturnal assisted ventilation, and continuous non- 
invasive ventilation(17, 18).
Endocrine and metabolic: Long-term steroids 
increase risk of osteoporosis. DMD patients 
commonly develop pathological low-trauma 
vertebral or long bone fractures (19). Bi annual 
dual energy X-ray absorptiometry (DEXA) 
scans and spine radiographs or lateral DEXA 
radiographs is recommended in steroid treated 
patients to identify asymptomatic vertebral 
12
Duchenne muscular dystophy: A short review and treatment update
Iran J Child Neurol. Spring 2021 Vol. 15 No. 2
fractures. Calcium and vitamin D supplementation 
is a proper means of prophylactic measure. Input 
from an endocrinologist may also be required to 
manage glucose intolerance and obesity and the 
need of intravenous biphosphonate. 
Gastrointestinal: Management to prevent obesity 
with propser diet should be provided. Dysphagia 
may develop which may be hazardous to 
speech. Due to chronic corticosteroid treatment, 
gastroprotective therapy should be given in the 
presence of symptoms. Gastric motility problems 
may lead to gastrostomy tube placement for 
undernutrition, dysphagia and aspiration at a later 
stage. 
Orthopaedic: It is necessary to monitor 
patients for joint contractures and potential 
scoliosis. Musculoskeletal problems require 
a multidisciplinary approach, including 
physiotherapy, occupational therapy, rehabilitation 
specialists, orthoses or surgery (20). The number 
of patients requiring this has diminished since the 
establishment of steroid therapy. 
Innovative therapies
Pharmacological: In this group active studies are 
to include several growth factors (such as insulin 
like growth factor-IGF-1) to promote regeneration, 
myostatin inhibitors to supress myostatin which is 
a negative muscle regulator, and vamorolone, an 
innovative steroid are currently being investigated 
as potential alternatives to corticosteroids aiming 
to maintain efficacy profile whilst reducing or 
avoiding the side effects associated with traditional 
corticosteroids. For this purpose NF-kB inhibitors 
(e.g edasalonexent) are also in consideration (21). 
There is another study actively recruting patients 
with pamrevlumab in order to block the fibrosis 
in muscle with this monoclonal antibody. For all 
ongonig clinical trials the reader is advised to visit 
the site www.clinicaltrials.gov One additional 
potentially interesting study is the tamoxifen study, 
currently going on in several countries in Europe. 
Tamoxifen has  anti-fibrotic properties in principal. 
All these are non-mutation dependent strategies. 
Cellular therapy: Several stem cell therapies 
have been considered since 1980s or even earlier. 
Myogenic stem cells, mesangioblasts (stem cells 
within vasculature), and direct myoblast transfer 
have been tried in DMD boys unfortunately with 
no success. The main limitation has been efficacy 
and developing immunological rejection. As it 
stands stem cell therapy in DMD is considered as 
‘stem cell tourism’. 
Molecular or genetic: We can name these newer 
generation efforts within the scope of individually 
based therapies. (22). We now have a working 
example: Ataluren (also called Translarna), has 
now been approved by several countries following 
some regulations as a treatment for DMD with 
a Management Access Agreement. Ataluren is 
a mutation specific therapy (“stop codon read 
through”), affecting approximately 15% of the 
DMD population. This is an oral molecule taken 
daily. It is considered as a ‘disease modifying 
molecule’, hence should not be considered as 
a cure (22, 23). Other therapeutic approaches 
currently tested in clinical trials include: mutation-
specific strategies aiming to correct the underlying 
genetic cause of the disease (e.g. exon skipping) 
(24-26). Eteplirsen is an antisense-oligonucleotide 
to skip exon 51 of the DMD gene. It is available 
on the market, however with reservations related 
to efficacy. Another potential similarly acting 
molecule for exon 51 skipping Drisapersen has not 
been approved at the final stage of the phase III 
clinical trial (25). Other academically interesting 
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anti-sense oligonucleotide drugs in the pipeline are 
Casimersen for exon 45, Golodirsen for exon 53, 
and Suvodirsen for exon 51 skipping, respectively 
(22). Among these Viltolarsen has been in the 
forefront with a backbone publication (ref). In 
my new institute in İstanbul, currently we have 8 
boys recruited on an international basis, a phase 
III placebo controlled trial (personal experience). 
Gene therapy can be considered on the horizon. 
Currently there are four groups engaged in delvering 
the DMD gene by varying methods. One example 
is the micro-dystrophin gene delivered in AAV9 
virus. Since 2018 four boys aged 4-6 were treated 
with gene therapy with an admirable improvement 
rate of 25-30% from the baseline (27). Curently 
there is a new series of boys with more than 60 
subjects and this is ongoing. However, there are 
multi-fold hurdles with gene therapy to include 
the timing, dosage, remainings of the viral vector, 
burden on innate immunity, and availablity on 
national levels (28). 
Scientific community is highly motivated with 
developments in innovative therapies in DMD just 
over a few years. Experts in the field possess very 
optimistic views for these new molecules. At this 
stage the discussion is not the time of emergence 
or availability of them. These drugs are wiil be 
expensive costing up to several million dollars 
which places governmental bodies and health care 
providers in a difficult position financially based 
upon the cumulative cost of several hundred re-
imbursements every year causing a true burden on 
the health economy globally (29, 30) 
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